The Research Of IP Financing Ability On Biotechnology Enterprise

Based on the development of knowledge economy in depth, each country on the earth thinks intellectual property strategy as focus. As the largest developing country, China should adjust to the new normal and take the construction of biotechnology economic power under the guidance of the innovation, harmonious, green, open and sharing new ideas. During the 12th five.year plan, biotechnology Enterprise has made remarkable achievements. However, the majority of small and medium.sized biotechnology companies are faced with financing predicament during the process of development. Therefore, they are urgent to seek a new kind of financing way. As the continuous improvement of national intellectual property strategy and constant improvement of financial markets, innovative companies start transferring the financing subject matter from physical assets to intellectual property rights. IP financing entered the historical arena,which offers a new thinking for biotechnology Enterprise finance.Though the government have continuously enhanced the management,application and protect of intellectual property rights, the process of IP finance is still slow and the number of biotechnology company using IP finance is few.So this paper takes biotechnology Enterprise as study subject and make an entire probing into the influencing factor of its IP financing ability. Based the AHP and BP networks, this article construct the evaluating pattern of biotechnology Enterprise IP financing ability, in order to promote the application and transform of biotechnology Enterprise IP rights. In this paper, the main work is as follows.(1) The Analysis of Biotechnology Enterprise IP Financing Status .The biotechnology enterprise develops fast and possesses amount of intellectual property.But, few biotechnology enterprises choose intellectual property finance now. The IP finance has a short deadline and provides a low credit line.(2 ) The screening and re-classification of the influencing factor of biotechnology Enterprise IP financing ability. Through studying the literature, this paper chooses the influencing factors. Based on the questionnaire survey, it screens and reclassifies factors by factor analysis.Eventually, we establish the index system model of biotechnology Enterprise IP financing ability and make a detailed analysis of the connotation of each evaluation index.(3 ) Using AHP to calculate the weight of each assessment index of biotechnology Enterprise IP financing ability. We choose seventy.six pharmaceutical and biological product enterprises on the Small and Medium Enterprise board and Growth Enterprise Market and search relevant financial data on the site such as CSMAR Solution, Flush software and China Securities Regulatory Commission. Besides, we acquire the score of qualitative index with the help of expert advice and knowledge. Finally, we calculate the evaluation scores of seventy.six enterprises potential IP financing ability, providing training and testing sample sets for the BP networks below.(4) Constructing the evaluation model of biotechnology Enterprise IP financing ability based on the BP networks. At first, we determine the BP network layers, the number of neurons in each layer, activation function, initial value, learning rate and so on. Through the simulation platform of MATLAB, the evaluation results which calculated using AHP are divided into sixty training samples and sixteen testing samples randomly, which to train and test the construction network model.Finally,the error is small and we gain a satisfactory result.Using AHP and BP network to evaluate biotechnology Enterprise IP financing ability, we can gain an accurate and reliable evaluation result,which will offer a new idea to evaluate biotechnology Enterprise IP financing ability and provide realistic guidance.